TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04458194

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard Care is used as a control condition. Cancer survivors assigned to this arm continue to receive standard care from their medical providers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: YOCAS©® yoga
Description: Yoga for Cancer Survivors, YOCAS©®, intervention is a low to moderate intensity mode of exercise that draws from two basic types of yoga; gentle Hatha and Restorative yoga. The program includes specific physical postures and mindfulness exercises focused on breathing and meditation. Cancer survivors will participate in 8 virtual YOCAS sessions (75 minutes/session, 2 times a week for 4 weeks) delivered via an electronic platform (e.g., Zoom)
Study: NCT05045417

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum level of IL-17
Description: Measurement of serum level of IL-17 :~1. To explore the role of IL-17 in systemic lupus erythematosus~2. To determine the relation between IL-17 and lupus disease activity~3. To analyze the correlation between IL-17 and internal organ affection (lupus nephritis , interstitial lung disease)

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum level of IL-17
Description: Measurement of serum level of IL-17 :~1. To explore the role of IL-17 in systemic lupus erythematosus~2. To determine the relation between IL-17 and lupus disease activity~3. To analyze the correlation between IL-17 and internal organ affection (lupus nephritis , interstitial lung disease)
Study: NCT05160441

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma Injection
Description: Minimum 2cc Leukocyte Poor Platelet Rich Plasma~The PRP will be prepared by drawing 60cc blood from the participant through venipuncture, spinning the blood sample in a centrifuge and then injecting the platelet rich plasma (approximately 2-5cc or max collected) into the study shoulder using ultrasound guidance. This sample will be prepared by the study provider (physician assistant or physician). Any leftover blood will be safely discarded per standard protocols.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid Injection
Description: 5cc Normal Saline + 2cc 10 mg/ml Triamcinolone Acetonide (Kenalog)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Delayed Platelet Rich Plasma Injection After Corticosteroid Injection Failure
Description: Participants randomized to the corticosteroid injection (CSI) group who report no improvement in their pain level at the 6 week post-CSI visit will be unblinded to their study injection (CSI) and will be offered the option to stay in the study and receive Platelet Rich Plasma injection.
Study: NCT05394350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1088
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1088
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1088
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1088
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1088
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1088
Description: Oral Tablet
Study: NCT06209372

Intervention type: PROCEDURE
Intervention: Group PENG
Description: Pericapsular Nerve Group Block (PENG)

Intervention type: DRUG
Intervention: Group C
Description: Tramadol infusion
Study: NCT05394350

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV Infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV Infusion
Study: NCT05018728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxelotor
Description: Voxelotor is taken orally once a day. Participants 12 years or older will take 1500 mg/day. Participants younger than 12 years of age will receive a dose based on their body weight to provide exposure corresponding to the adult dose of 1500 mg/day.
Study: NCT05547542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-354
Description: Oral solution/capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-354
Description: Oral solution/capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]-LY2795050
Description: IV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]-carfentanil
Description: IV injection
Study: NCT05252702

Intervention type: DEVICE
Group type: OTHER
Intervention: Aveir DR Leadless Pacemaker System
Description: Patients will undergo a dual chamber leadless pacemaker system implant wherein a leadless pacemaker will be implanted in the right ventricle and right atrium
Study: NCT04290897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anhydrous Enol-oxaloacetate
Description: Given PO
Study: NCT06090591

Intervention type: OTHER
Intervention: SGLT-2 inh therapy, CIED implantation, thromboaspiration,
Description: long-term follow up and observation of patients treated in Cardiology department in the tertiary center and University hospital

Intervention type: OTHER
Intervention: SGLT-2 inh therapy, CIED implantation, thromboaspiration,
Description: long-term follow up and observation of patients treated in Cardiology department in the tertiary center and University hospital

Intervention type: OTHER
Intervention: SGLT-2 inh therapy, CIED implantation, thromboaspiration,
Description: long-term follow up and observation of patients treated in Cardiology department in the tertiary center and University hospital

Intervention type: OTHER
Intervention: SGLT-2 inh therapy, CIED implantation, thromboaspiration,
Description: long-term follow up and observation of patients treated in Cardiology department in the tertiary center and University hospital

Intervention type: OTHER
Intervention: SGLT-2 inh therapy, CIED implantation, thromboaspiration,
Description: long-term follow up and observation of patients treated in Cardiology department in the tertiary center and University hospital
Study: NCT04290897

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06189365

Intervention type: DEVICE
Intervention: Left Atrial Appendage (LAA) closure procedure with Amplatzer Amulet LAA occluder
Description: Subject will receive the Left Atrial Appendage (LAA) closure procedure with Amplatzer Amulet LAA occluder.
Study: NCT05049824

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self Forming Magnetic (SFM) Anastomosis System
Description: The SFM will be placed using an endoscope in the duodenum and laparoscopically into the ileum. A compression anastomosis will be created in each of the subjects and the diversion of enteral flow from the duodenum to ileum will create a metabolic effect that will induce weight loss and impact metabolic disease indicators
Study: NCT05073432

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Usability of the Discussion Prioritization Tool (DPT) by completing Geriatric Assessment and Conjoint Analysis
Study: NCT06290323

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus lumborum block
Description: Posterior quadratus lumborum block

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Placebo
Description: Patients in the first group are the control group and after spinal anesthesia, the sensory block is formed, the lithotomy position will be taken for the surgical procedure.
Study: NCT06536881

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fasting
Description: The dietician will review the patient's chemotherapy schedule, and confirm the fasting window (as windows may be 24, 26 or 48 hours; and chemotherapy start times can vary from patient to patient).
Study: NCT06641999

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tinnitus Implant System
Description: Implanted with Tinnitus Implant System: Active Implantable Medical Device
Study: NCT06642051

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Intensity focused ultrasound
Description: Sonablate High Intensity Focused Ultrasound system to ablate incompetent veins of the periphery
Study: NCT05790031

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intelligent Nighttime Brace
Description: Participants will be invited to undergo a fitting session of intelligent nighttime brace. After the fitting, participants will join a 6-month wear trial of the intelligent nighttime brace. Participants are required to wear the intelligent nighttime brace for 8 hours a day during sleeping and compliance will be recorded by an intelligent monitoring system. Participants will be invited to undergo assessments before the wear trial, after the trials of 3 months and after the trial of 6 months. The measure outcomes of the assessment include 1)ultrasound scanning image, 2)3D body scanning, 3)garment pressure, 4) questionnaires
Study: NCT06421311

Intervention type: DRUG
Intervention: nivolumab
Description: According to approved product label (France)
Study: NCT06237647

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid, HA
Description: improve tissue repair

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid, HA
Description: improve tissue repair
Study: NCT05996874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive Dose 1 oral semaglutide D for the first 5 days followed by Dose 2 of oral semaglutide D for another 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive Dose 1 oral semaglutide D for the first 5 days followed by Dose 2 of oral semaglutide D for another 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive Dose 1 oral semaglutide D for the first 5 days followed by Dose 2 of oral semaglutide D for another 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive Dose 1 oral semaglutide D for the first 5 days followed by Dose 2 of oral semaglutide D for another 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive Dose 1 oral semaglutide D for the first 5 days followed by Dose 2 of oral semaglutide D for another 5 days.
Study: NCT05550428

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: home-based-exercise
Description: All the participants were instructed on the proper performance of the exercise regimen by a senior physiotherapist before the commencement of the intervention. Subjects were then instructed to perform the home-based exercises on their own twice a week for eight weeks. One dedicated research assistant kept a weekly record of the participants' physical activity.~sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home-based-exercise
Description: All the participants were instructed on the proper performance of the exercise regimen by a senior physiotherapist before the commencement of the intervention. Subjects were then instructed to perform the home-based exercises on their own twice a week for eight weeks. One dedicated research assistant kept a weekly record of the participants' physical activity.~sessions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active pulsed electromagnetic field（PEMF）therapy
Description: Alternating legs on consecutive visits were exposed to either PEMF or sham therapy for eight weeks for a total of 16 PEMF sessions per participant, each leg receiving 8 exposures.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: shame pulsed electromagnetic field（PEMF）therapy
Description: Alternating legs on consecutive visits were exposed to either PEMF or sham therapy for eight weeks for a total of 16 sham PEMF sessions per participant, each leg receiving 8 exposures.
Study: NCT05996874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive Dose 1 oral semaglutide D for the first 5 days followed by Dose 2 of oral semaglutide D for another 5 days.
Study: NCT05912634

Intervention type: PROCEDURE
Intervention: Conservative TAAD-R
Description: Cardiac arrest will be ensured using antegrade potassium-rich cardioplegia solution delivered directly into the coronary ostium or after coronary sinus cannula insertion, in patients with aortic regurgitation aorta will be resected down to the sinotubular junction and the thrombus located in the false lumen of the aortic root will be removed so that the aortic lesion could be visualized. The commissures will be resuspended using 4-0 or 5-0 sutures reinforced with a Teflon pledget over each commissure. A 4-0 or 5-0 polypropylene suture will be chosen to seal the proximal anastomosis and this suture line will also be used to secure the intima to the adventitia. In patients revealing normal-sized aortic roots associated with poor-quality valve leaflets, concomitant aortic valve replacement with conventional xenograft or mechanical prosthesis will be preferred.

Intervention type: PROCEDURE
Intervention: Extensive TAAD- R
Description: Patients who experienced dilatation of the sinuses of Valsalva \>4.5 cm in diameter on computed tomography imaging, those with connective tissue disease, or those in whom intimal tears extended into the sinuses, will undergoing replacement of the aortic root using a biologic or mechanical composite valve graft or valve-sparing root reimplantation procedure.Total arch replacement procedures (TARP) will fulfilled with the use of deep hypothermic circulatory arrest and with either antegrade or retrograde cerebral perfusion, maintaining systemic cooling between 19°C to 25°C and depending on the surgeon's practice.TARPs will be carried out using 1- and 4-branch grafts and involved the resection of all the aortic tissue up to the left common carotid artery (total arch)
Study: NCT05612698

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: Supervised Aerobic Training intervention (AT): Perform 50 minutes/day, 3 days/week, totalling 150 min/week at moderate intensity, as recommended by WHO, in a range of 65-75% HRMax. Due to any form of aerobic exercise involving large muscle groups and causes sustained increases in HR is likely to be beneficial, the type of aerobic exercise will be agreed with each group of patients, varying from 4 to 8 people. There will be a choice of ex-ercises and participants will be able to choose a combination of up to 2 different exercises. The participants' choice of the type of activity to be performed is expected to encourage greater adherence. The range of exercises will be brisk walking or running, swimming, and/or aerobic dancing.
Study: NCT05879159

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Survey

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Survey
Study: NCT05612698

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic training plus resistance training
Description: Supervised Aerobic Training plus Resistance Training intervention (AT+RT): Perform 50 minutes/day, 3 days/week, starting with 50% of 1-repetition maximum (1-RM) and follow a progression of increasing loads up to 75% of 1-RM for optimal gains in strength and insulin action. In each session, between 5 and 10 exercises will be worked on, per-forming 10-15 repetitions, and progressing to 8-10 lifting as the weight increases, involving the major muscle groups from the core, lower body and upper body. In all sessions there will be a 3-minute warm-up at the beginning of the session and a 2-minute cool-down at the end of the session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensive interval training
Description: Supervised High Intensive Interval Training intervention (HIIT): To be considered high intensive the heart rate needs to be above ≥85%. Perform 25 minutes/day, 3 days/week, totalling 75 min/week at a vigorous intensity, as recommended by WHO. Starting with 4 intervals lasting 1 minute keeping in a range of 85-90% HRMax, separated by 1 minute of low intensity activity (no static) (4 × 1 min intervals.) A progression will be followed by increasing the number of circuits, up to 10 (10 × 1 min intervals) \[25, 78, 79\]. In all sessions there will be a 3-minute warm-up at the beginning of the session and a 2-minute cool-down at the end of the session. Although the target popula-tion is a sedentary population, we expect the HIIT approach, despite being high intensity, to be well received, due to its growing popularity, as demonstrated by a study in which 62% of inactive participants preferred HIIT to other types of exercise.
Study: NCT05938946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L608 Inhalation Solution
Description: subjects will be randomized at a ratio of 1:1 (for Sentinel dosing) followed by 5:1 for rest of the cohort to receive the assigned dose of L608 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo solution
Description: subjects will be randomized at a ratio of 1:1 (for Sentinel dosing) followed by 5:1 for rest of the cohort to receive the assigned dose of L608 or placebo
Study: NCT05495126

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard Limbic Access pathway
Description: Relevant information for clinical referral (e.g. demographics) and basic clinical information (e.g. PHQ-9 \& Gad-7 scores) are collected during the self-referral process which is then attached to the referral notes in order to facilitate the clinical assessment conducted by the clinician.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Limbic Access with AI pathway
Description: The same information as in the Limbic Access pathway is collected. However, additional information (i.e. disorder specific questionnaires) are collected for the most likely problem descriptors based on the ML-model predictions.~All information is attached to the referral in order to facilitate the clinical assessment conducted by the clinician.
Study: NCT05894083

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Cohort A will undergo initial surgical resection of the primary and neck dissection with pathologic features directing predetermined adjuvant treatment. Pathology of the primary and nodal specimens will then be reviewed as to determine the next intervention per protocol. Based on operative findings including degree of nodal involvement, extracapsular spread, perineural invasion, and lymphovascular involvement, patients will be designated to adjuvant treatment arms consisting of observation, adjuvant radiation, or adjuvant chemoradiation.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Description: Patients will receive an initial plan with a single prescription of 30 Gy in 15 fractions to PTV_High and PTV_Low with RT given once daily, 5 days a week (Monday through Friday). After analysis of mid-treatment PET/CT, the remaining radiation treatment will be delivered as a conedown to the gross disease only. Patients will be planned to receive a total dose of 70 Gy, 54 Gy, or 44 Gy to PTV_High in 2 Gy per fraction.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Chemoradiation
Description: Patients will receive an initial plan with a single prescription of 30 Gy in 15 fractions to PTV_High and PTV_Low with RT given once daily, 5 days a week (Monday through Friday). After analysis of mid-treatment PET/CT, the remaining radiation treatment will be delivered as a conedown to the gross disease only. Patients will be planned to receive a total dose of 70 Gy, 54 Gy, or 44 Gy to PTV_High in 2 Gy per fraction.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation
Description: Cohort A will undergo initial surgical resection of the primary and neck dissection with pathologic features directing predetermined adjuvant treatment. Pathology of the primary and nodal specimens will then be reviewed as to determine the next intervention per protocol. Based on operative findings including degree of nodal involvement, extracapsular spread, perineural invasion, and lymphovascular involvement, patients will be designated to adjuvant treatment arms consisting of observation, adjuvant radiation, or adjuvant chemoradiation.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Post-operative radiation
Description: Patients will receive adjuvant radiation based on pathologic features.Total radiation treatment doses and prescriptions will include 36 Gy in 18 fractions, 50 Gy in 25 fractions and 60 Gy in 30 fractions.
Study: NCT04696575

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Given PO
Study: NCT05352399

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NeuViCare application
Description: Intervention arm participants will engage with NeuViCare AI, including all variations of its 5 components: 1) NeuViCare Planner - enables review of ordered tests and external resources recommended by the care provider; 2) NeuViCare Task-Support Service - provides context-sensitive, personalized text-based assistance to help patients' complete care plan captured in the NeuViCare Planner; 3) NeuViCare Resource Advisor - presents trusted, unbiased advice to locate nearby resources listed within their care plan; 4) NeuViCare Advisor - educates and trains Persons Living With Dementia (PLWD) and their care partners at the moment of need; and 5) NeuViCare Community Hub - a safe virtual space which enables care partners to interact with other peer care partners to gain their experiential knowledge and emotional support.